Stock Events

Stock Events

Illumina 

€118.66
472
-€0.38-0.32% Tuesday 19:55

Statistics

Day High
121.14
Day Low
116.46
52W High
130.92
52W Low
66.03
Volume
121
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q4 2025
Q1 2026
Next
0.9
0.98
1.06
1.15
Expected EPS
1.04661200363
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ILU.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pacific Biosciences of California
PACB
Mkt Cap496.78M
Pacific Biosciences offers long-read sequencing technologies that compete with Illumina's short-read sequencing platforms, providing an alternative in genomic sequencing.
Thermo Fisher Scientific
TMO
Mkt Cap174.37B
Thermo Fisher Scientific competes with Illumina in the life sciences and diagnostics market, offering a range of sequencing and genetic analysis products.
Bio-Rad Laboratories
BIO.B
Mkt Cap8.84B
Bio-Rad Laboratories provides a variety of research and clinical diagnostic products that compete with Illumina's offerings in genomic and molecular diagnostics.
Qiagen NV
QGEN
Mkt Cap7.06B
Qiagen competes with Illumina in the provision of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research.
Roche
RHHBY
Mkt Cap328.49B
Roche Holding AG competes through its acquisition of GenMark Diagnostics and a strong portfolio in diagnostics and genomic sequencing, challenging Illumina's market share.
Agenus
AGEN
Mkt Cap147.45M
Agilent Technologies offers a range of products for genomics and molecular biology that compete with Illumina's sequencing and array technologies.
Intellia Therapeutics
NTLA
Mkt Cap1.58B
Intellia Therapeutics is involved in CRISPR technology, which, while not a direct competitor in sequencing, competes in the broader genomics market where Illumina operates.
Editas Medicine
EDIT
Mkt Cap283.93M
Editas Medicine is focused on gene editing technology, representing a competitive force in the genomics industry by offering alternative approaches to genetic analysis and modification.
CRISPR Therapeutics
CRSP
Mkt Cap4.98B
CRISPR Therapeutics is engaged in gene-based medicine, indirectly competing with Illumina by advancing the application of genomics in therapeutic development.

About

There is no Profile data available for ILU.SG.
Show more...
CEO
Country
Germany
ISIN
US4523271090

Listings

MU
DE
ILU.MU
LSE
GB
0J8Z.LSE
STU
DE
ILU.STU
MI
IT
1ILMN.MI

0 Comments

Share your thoughts

FAQ

What is Illumina stock price today?▼
The current price of ILU.STU is €118.66 EUR — it has decreased by -0.32% in the past 24 hours. Watch Illumina stock price performance more closely on the chart.
What is Illumina stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Illumina stocks are traded under the ticker ILU.STU.
Is Illumina stock price growing?▼
ILU.STU stock has risen by +14.82% compared to the previous week, the month change is a +7.91% rise, over the last year Illumina has showed a +79.71% increase.
When is the next Illumina earnings date?▼
Illumina is going to release the next earnings report on August 12, 2026.
What were Illumina earnings last quarter?▼
ILU.STU earnings for the last quarter are 0.98 EUR per share, whereas the estimation was 0.9 EUR resulting in a +9.06% surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is Illumina located?▼
Illumina operates in the Materials sector.
When did Illumina complete a stock split?▼
Illumina has not had any recent stock splits.